309 related articles for article (PubMed ID: 26614517)
1. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
[TBL] [Abstract][Full Text] [Related]
2. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
[TBL] [Abstract][Full Text] [Related]
3. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
6. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
7. The role of temozolomide in the treatment of aggressive pituitary tumors.
Liu JK; Patel J; Eloy JA
J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pituitary neoplasms with temozolomide: a review.
Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide in aggressive pituitary adenomas and carcinomas.
Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
13. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Hirohata T; Ishii Y; Matsuno A
Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
[TBL] [Abstract][Full Text] [Related]
14. Use of temozolomide in aggressive pituitary tumors: case report.
Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
[TBL] [Abstract][Full Text] [Related]
15. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
Widhalm G; Wolfsberger S; Preusser M; Woehrer A; Kotter MR; Czech T; Marosi C; Knosp E
Cancer; 2009 Mar; 115(5):1070-80. PubMed ID: 19156926
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
[TBL] [Abstract][Full Text] [Related]
17. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
Elbelt U; Schlaffer SM; Buchfelder M; Knappe UJ; Vila G; Micko A; Deutschbein T; Unger N; Lammert A; Topuzoglu-Müller T; Bojunga J; Droste M; Johanssen S; Kolenda H; Ritzel K; Buslei R; Strasburger CJ; Petersenn S; Honegger J
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31746334
[TBL] [Abstract][Full Text] [Related]
19. Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.
Ghazi AA; Rotondo F; Kovacs K; Amirbaigloo A; Syro LV; Fathalla H; Di Ieva A; Cusimano MD
Endocr Pathol; 2015 May; 26(2):135-9. PubMed ID: 25716461
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas.
Minniti G; Paolini S; Rea MLJ; Isidori A; Scaringi C; Russo I; Osti MF; Cavallo L; Esposito V
J Neurooncol; 2020 Aug; 149(1):123-130. PubMed ID: 32632895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
